Stockreport

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B [Yahoo! Finance]

Precision BioSciences, Inc.  (DTIL) 
Last precision biosciences, inc. earnings: 11/12 07:15 am Check Earnings Report
PDF PBGENE-HBV is the first in vivo gene editing program for chronic hepatitis B virus to move into global clinical trials Company to host investor event highlighting cli [Read more]